PaTHway Phase 3 Trial Analysis

Demographics and Baseline Characteristics (continued) Characteristics Race - n (%) American Indian or Alaska Native Asian Black or African American Native Hawaiian or Other Pacific Islander White Other Geographic Region - n (%) North America Europe Pathway TRIAL TransCon PTH (N = 61) Placebo (N = 21) 0 0 3 (4.9) 2 (9.5) 0 0 57 (93.4) 0 0 19 (90.5) 1 (1.6) 0 39 (63.9) 22 (36.1) 12 (57.1) 9 (42.9) 11 Data on file, Ascendis Pharma 2022. TransCon PTH is an investigational product candidate. For investor communication only. Not for use in product promotion. Not for further distribution. ascendis pharma

View entire presentation